The effects of memantine versus placebo on visual functions of patient with optic neuritis

In patients with optic neuritis, is Memantine as good as or better than placebo for improving visual functions?

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000350921

Enrollment

Registered

2011-04-05

Start date

2010-04-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Evaluation of the neuroprotective effect of Memantine in visual function of patients with optic neuritis. Our hypothesis was that Memantine helps for better improvement of visual function in acute optic neuritis.

Interventions

Memantine tablets for treatment group for 3 weeks orally(5mg/day for the first week and 10 mg/ day for the next two weeks)

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

10 Years to 50 Years

Healthy volunteers

Inclusion criteria

Isolated acute optic neuritis with duration of less than 8 days as patient declares

Exclusion criteria

anti-convulsants, barbiturates, neuroleptics, Amantadine hydrochlorothiazids, digoxin and dextrometorphan (interacting with memantine) Pregnancy or nursing Renal disease

Outcome results